<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group>
<journal-title>PLoS ONE</journal-title></journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, USA</publisher-loc></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">PONE-D-13-35586</article-id>
<article-id pub-id-type="doi">10.1371/journal.pone.0084230</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Mathematics</subject><subj-group><subject>Statistics</subject><subj-group><subject>Biostatistics</subject><subject>Statistical methods</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Clinical research design</subject><subj-group><subject>Meta-analyses</subject></subj-group></subj-group><subj-group><subject>Drugs and devices</subject><subj-group><subject>Adverse reactions</subject><subject>Drug information</subject><subject>Drug interactions</subject><subject>Drug research and development</subject></subj-group></subj-group><subj-group><subject>Gastroenterology and hepatology</subject><subj-group><subject>Gastrointestinal cancers</subject></subj-group></subj-group><subj-group><subject>Oncology</subject><subj-group><subject>Cancer treatment</subject><subj-group><subject>Chemotherapy and drug treatment</subject></subj-group></subj-group><subj-group><subject>Cancers and neoplasms</subject><subj-group><subject>Gastrointestinal tumors</subject></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Comparison of the Efficacy and Safety of S-1-Based and Capecitabine-Based Regimens in Gastrointestinal Cancer: A Meta-Analysis</article-title>
<alt-title alt-title-type="running-head">S-1 and Capecitabine in Gastrointestinal Cancer</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Zhang</surname><given-names>Xunlei</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Cao</surname><given-names>Chunxiang</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Zhang</surname><given-names>Qi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Chen</surname><given-names>Yi</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Gu</surname><given-names>Dongying</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Shen</surname><given-names>Yunzhu</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Gong</surname><given-names>Yongling</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Chen</surname><given-names>Jinfei</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Tang</surname><given-names>Cuiju</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib>
</contrib-group>
<aff id="aff1"><label>1</label><addr-line>Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China</addr-line></aff>
<aff id="aff2"><label>2</label><addr-line>Department of Oncology, Nanjing First Hospital, Medical School of Southeast University, Nanjing, China</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple"><name name-style="western"><surname>Bertolini</surname><given-names>Francesco</given-names></name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/></contrib>
</contrib-group>
<aff id="edit1"><addr-line>European Institute of Oncology, Italy</addr-line></aff>
<author-notes>
<corresp id="cor1">* E-mail: <email xlink:type="simple">tangcuiju@tom.com</email></corresp>
<fn fn-type="conflict"><p>The authors have declared that no competing interests exist.</p></fn>
<fn fn-type="con"><p>Conceived and designed the experiments: XZ CT. Performed the experiments: XZ CC. Analyzed the data: QZ YC. Contributed reagents/materials/analysis tools: DG YS. Wrote the paper: XZ. Reviewed and checked the paper: YG JC.</p></fn>
</author-notes>
<pub-date pub-type="collection"><year>2014</year></pub-date>
<pub-date pub-type="epub"><day>2</day><month>1</month><year>2014</year></pub-date>
<volume>9</volume>
<issue>1</issue>
<elocation-id>e84230</elocation-id>
<history>
<date date-type="received"><day>29</day><month>8</month><year>2013</year></date>
<date date-type="accepted"><day>21</day><month>11</month><year>2013</year></date>
</history>
<permissions>
<copyright-year>2014</copyright-year>
<copyright-holder>Zhang et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions>
<abstract><sec>
<title>Purpose</title>
<p>Oral fluoropyrimidine (S-1, capecitabine) has been considered as an important part of various regimens. We aimed to evaluate the efficacy and safety of S-1-based therapy versus capecitabine -based therapy in gastrointestinal cancers.</p>
</sec><sec>
<title>Methods</title>
<p>Eligible studies were identified from Pubmed, EMBASE. Additionally, abstracts presented at American Society of Clinical Oncology (ASCO) conferences held between 2000 and 2013 were searched to identify relevant clinical trials. The outcome included overall survival (OS), progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR) and advent events.</p>
</sec><sec>
<title>Results</title>
<p>A total of 6 studies (4 RCTs and 2 retrospective analysis studies) containing 790 participants were included in this meta-analysis, including 401 patients in the S-1-based group and 389 patients in the capecitabine-based group. Results of our meta-analysis indicated that S-1-based and capecitabine-based regimens showed very similar efficacy in terms of PFS (HR 0.92, 95% CI 0.78–1.09, <italic>P</italic> = 0.360), OS (HR 1.01, 95% CI 0.84–1.21, <italic>P</italic> = 0.949), ORR (HR 1.04, 95% CI 0.87–1.25, <italic>P</italic> = 0.683) and DCR (HR 1.02, 95% CI 0.94–1.10, <italic>P</italic> = 0.639). There was also no significant difference in toxicity between regimens other than mild more hand–foot syndrome in capecitabine-based regimens.</p>
</sec><sec>
<title>Conclusion</title>
<p>Both the S-1-based and capecitabine-based regimens are equally active and well tolerated, and have the potential of backbone chemotherapy regimen in further studies of gastrointestinal cancers.</p>
</sec></abstract>
<funding-group><funding-statement>The work was supported by a grant from The Project of Plans for the Development of Science and Technology of Nanjing, China; Grant Number: 201208020; Website: <ext-link ext-link-type="uri" xlink:href="http://www.njh.gov.cn" xlink:type="simple">http://www.njh.gov.cn</ext-link>. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="10"/></counts></article-meta>
</front>
<body><sec id="s1">
<title>Introduction</title>
<p>Gastrointestinal cancers, especially gastric and colorectal cancers, are a major global health concern. Previous studies suggest that factors such as dietary, lifestyle, other personal exposures, and genetic factors might increase the susceptibility to developing gastrointestinal cancer <xref ref-type="bibr" rid="pone.0084230-Desauw1">[1]</xref>. Gastric cancer (GC) and colorectal cancer (CRC) are the third and the fourth common cancers in the world behind lung cancer and breast cancer, and are also the major causes of cancer-related deaths globally <xref ref-type="bibr" rid="pone.0084230-Shin1">[2]</xref>, <xref ref-type="bibr" rid="pone.0084230-Shridhar1">[3]</xref>. The most commonly used regimens for GC are combination chemotherapy consisting of a fluoropyrimidine (5-fluorouracil or oral fluoropyrimidine, 5-Fu) plus a platinum agent with or without docetaxel or anthracyclines <xref ref-type="bibr" rid="pone.0084230-VanCutsem1">[4]</xref>, <xref ref-type="bibr" rid="pone.0084230-Cunningham1">[5]</xref>, <xref ref-type="bibr" rid="pone.0084230-Koizumi1">[6]</xref>, <xref ref-type="bibr" rid="pone.0084230-Kang1">[7]</xref>. Doublet combination chemotherapy plus targeted agents is a widely used treatment strategy for the first-line treatment of patients with CRC, and oxaliplatin plus either fluorouracil or capecitabine is one of the reference doublet cytotoxic chemotherapy strategies <xref ref-type="bibr" rid="pone.0084230-Cassidy1">[8]</xref>, <xref ref-type="bibr" rid="pone.0084230-deGramont1">[9]</xref>.</p>
<p>From the above-mentioned,fluoropyrimidines have remained the most commonly prescribed agents for gastrointestinal cancers in various settings. 5­FU administered as a continuous infusion by a portable pump provides prolonged exposure and modest improvement in efficacy. However, the infusion is inconvenient and unsafe, for it can plague with more catheter­related events hematological toxicity and hand–foot syndrome <xref ref-type="bibr" rid="pone.0084230-Schoffski1">[10]</xref>, <xref ref-type="bibr" rid="pone.0084230-1">[11]</xref>.</p>
<p>For this reason, oral fluoropyrimidine (S-1, capecitabine) has been studied as a substitute for continuous infusion of 5-FU. S-1 is a novel oral fluoropyrimidine consisting of a 5-FU prodrug, tegafur, and the dihydropyrimidine dehydrogenase inhibitor, 5-chloro-2, 4-dihydroxypyridine and the orotate phosphoribosyl transferase inhibitor, potassium oxonate, which suppresses the gastrointestinal toxicity of tegafur <xref ref-type="bibr" rid="pone.0084230-Maehara1">[12]</xref>. The FLAGS trial revealed a similar efficacy and better toxicity profile of S-1 compared to infusional 5-FU <xref ref-type="bibr" rid="pone.0084230-Ajani1">[13]</xref>. Capecitabine is an oral fluoropyrimidine, which is metabolized primarily in the liver and converted in tumor tissues to 5-FU by the enzyme thymidine phosphorylase, which is present in higher concentrations in tumor cells than in normal cells. Additionally, meta-analysis of 2 trials showed that OS was superior in the patients treated with capecitabine combinations than in the patients treated with 5-FU combinations <xref ref-type="bibr" rid="pone.0084230-Okines1">[14]</xref>. By virtue of their oral formulations, promising efficacy, and favourable toxicity profiles, S-1 and capecitabine may be particularly attractive for elderly cancer patients <xref ref-type="bibr" rid="pone.0084230-Lee1">[15]</xref>.</p>
<p>Previous study compared the efficacy and safety of S-1 and capecitabine in patients with GC, showing that there were no significant differences in objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) between the S-1 and capecitabine groups, although some results showed capecitabine has a slightly longer OS (statistically not significant) in addition to a higher rate of adverse events such as the hand–foot syndrome and diarrhea<xref ref-type="bibr" rid="pone.0084230-Lee1">[15]</xref>, <xref ref-type="bibr" rid="pone.0084230-Kim1">[16]</xref>, <xref ref-type="bibr" rid="pone.0084230-Seol1">[17]</xref>, <xref ref-type="bibr" rid="pone.0084230-Shitara1">[18]</xref>. however, when compared in CRC, Hong et al. found S-1 group have a nearly 2 months longer in PFS than capecitabine group from a phase III trial, while Zang et al. reported capecitabine group have a 3 months longer in OS from a newest phase II trial <xref ref-type="bibr" rid="pone.0084230-Hong1">[19]</xref>.</p>
<p>In gastrointestinal cancer, several randomized controlled trials (RCTs) and retrospective research, comparing S-1 with capecitabine in mono or combined therapy, have been conducted, with not consistent completely, none of which have allowed the definite conclusions about the efficacy and safety of these two therapies. Additionly, there has been no meta-analysis to detect the treatment differences with greater power of statistical comparisons. Therefore, we conducted a meta-analysis to give an overview of the results of all eligible studies with the aim of investigating the differences of the efficacy and safety between S-1 and capecitabine groups in gastrointestinal cancers.</p>
</sec><sec id="s2" sec-type="methods">
<title>Methods</title>
<sec id="s2a">
<title>Search strategy</title>
<p>We did a comprehensive search of citations from Pubmed, EMBASE from April 1966 to July 2013 using the following terms, which included in their titles, abstracts, or keyword lists: ‘S-1’, ‘capecitabine’, ‘gastric cancer’, ‘colorectal cancer’, ‘gastrointestinal cancer’ without any language restriction. In addition, all abstracts and virtual meeting presentations from the American Society of Clinical Oncology (ASCO) conferences held between 2000 and 2013 were also searched for relevant research. We included studies that reported the patient numbers and characteristics, treatment regimen and study outcome including efficacy and safety. We resolved disagreements by consensus or by a third reviewer if necessary.</p>
</sec><sec id="s2b">
<title>Study selection</title>
<p>Studies that met the following criteria were included in the meta-analysis: (i) patients with gastrointestinal cancer at baseline; (ii) studies comparing S-1-based therapy with capecitabine -based therapy: mono or combined chemotherapy with S-1 versus capecitabine and not confounded by additional agents or interventions (i.e. in the combination chemotherapy, the control and experimental arms had to differ only by S-1 and capecitabine components); (iii) randomised controlled trials (RCTs), quasi-RCTs, and retrospective or prospective controlled studies. Two reviewers independently assessed each study for inclusion using a standardized form with eligibility criteria. Each study was fully examined to eliminate duplicates.</p>
</sec><sec id="s2c">
<title>Data extraction</title>
<p>Two reviewers extracted data from each report independently and reached a consensus on all items. The following data were retrieved: study authors, publication year, phase design, number of patients, sex, median age, cancer type, chemotherapy regimen, median OS, PFS, and adverse events (AEs). Hazard ratios (HRs) for OS and PFS were extracted directly from the original studies or were estimated indirectly by reading off survival curves as suggested by Parmar and colleagues <xref ref-type="bibr" rid="pone.0084230-Parmar1">[20]</xref>.</p>
</sec><sec id="s2d">
<title>Statistical analysis</title>
<p>OS and PFS rate was used as the primary outcome measure. Secondary outcome measures evaluated were ORR (number of partial and complete responses), disease control rate (DCR: number of partial and complete responses and stable disease) and toxicities (published by the authors with the most frequently reported events analyzed) <xref ref-type="bibr" rid="pone.0084230-Therasse1">[21]</xref>, <xref ref-type="bibr" rid="pone.0084230-Sutton1">[22]</xref>. Statistical analysis of the overall hazard ratio (HR) and the 95% CIs for OS and PFS, the risk ratio (RR) for ORR, DCR and AEs was calculated using STATA version 10.0 (Stata Corporation, College Station, Texas, USA). We also compared the pooled estimates of the above efficacy outcomes for subpopulations stratified by age, combined medicine, treatment schedule, trial type and cancer type. An HR&lt;1 indicates a favorable outcome in the S-1-based regimens for OS and PFS. An RR&gt;1 favors S-1-based group for response rate, or indicates more toxicity or treatment-related deaths in the S-1-based group. The efficacy and safety of pooled estimates were calculated using the fixed-effects model first <xref ref-type="bibr" rid="pone.0084230-Sutton1">[22]</xref>. If any heterogeneity existed, a random-effects model was applied in a sensitivity analysis. The traditional Q test and the I<sup>2</sup> statistic were used to evaluate heterogeneity and a P&lt;0.1 was considered as heterogeneity between studies. The presence of publication bias was evaluated by using the Begg's and Egger's tests <xref ref-type="bibr" rid="pone.0084230-Begg1">[23]</xref>, <xref ref-type="bibr" rid="pone.0084230-Egger1">[24]</xref>. A 2-tailed P value of less than 0.05 was judged as statistically significant.</p>
</sec></sec><sec id="s3">
<title>Results</title>
<sec id="s3a">
<title>Search results and description of the studies</title>
<p>The study flow diagram is shown in <xref ref-type="fig" rid="pone-0084230-g001">Figure 1</xref>. In total, 6 studies <xref ref-type="bibr" rid="pone.0084230-Lee1">[15]</xref>, <xref ref-type="bibr" rid="pone.0084230-Kim1">[16]</xref>, <xref ref-type="bibr" rid="pone.0084230-Seol1">[17]</xref>, <xref ref-type="bibr" rid="pone.0084230-Shitara1">[18]</xref>, <xref ref-type="bibr" rid="pone.0084230-Hong1">[19]</xref>, <xref ref-type="bibr" rid="pone.0084230-Zang1">[25]</xref> fulfilled the inclusion criteria of this meta-analysis, with four studies on GC and two studies on CRC. Among the selected studies, 4 were prospective clinical trials (3 randomized controlled phase II trial, 1 randomized controlled phase III trial) and 2 were retrospective analysis studies. All the patients included in our pooled analysis were Asian population.</p>
<fig id="pone-0084230-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0084230.g001</object-id><label>Figure 1</label><caption>
<title>Flow diagram summarizing the search strategy.</title>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0084230.g001" position="float" xlink:type="simple"/></fig>
<p>A total of 790 participants were included in this meta-analysis, including 401 patients in the S-1-based group and 389 patients in the capecitabine-based group. Patient enrollment ranged between 72 and 340, and median age of patients ranged from 60 to 74. The used drugs were S-1, capecitabine, cisplatin, and oxaliplatin, and regimens were similar with respect to doses in every trial. The baseline characteristics of the 6 studies were summarized in <xref ref-type="table" rid="pone-0084230-t001">Table 1</xref>. All the studies included in the meta-analysis were reasonably well conducted and had balanced populations.</p>
<table-wrap id="pone-0084230-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0084230.t001</object-id><label>Table 1</label><caption>
<title>Characteristics of literatures included in the meta-analysis.</title>
</caption><alternatives><graphic id="pone-0084230-t001-1" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0084230.t001" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Author</td>
<td align="left" rowspan="1" colspan="1">Year</td>
<td align="left" rowspan="1" colspan="1">Country</td>
<td align="left" rowspan="1" colspan="1">Study design</td>
<td align="left" rowspan="1" colspan="1">Cancer type</td>
<td align="left" rowspan="1" colspan="1">Chemotherapy regimen</td>
<td align="left" rowspan="1" colspan="1">Age S/C (Year)</td>
<td align="left" rowspan="1" colspan="1">Number S/C</td>
<td align="left" rowspan="1" colspan="1">Median PFS S/C (Months)</td>
<td align="left" rowspan="1" colspan="1">Median OS S/C (Months)</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Kim<xref ref-type="bibr" rid="pone.0084230-Kim1">[16]</xref></td>
<td align="left" rowspan="1" colspan="1">2012</td>
<td align="left" rowspan="1" colspan="1">korea</td>
<td align="left" rowspan="1" colspan="1">RCT II</td>
<td align="left" rowspan="1" colspan="1">GC</td>
<td align="left" rowspan="1" colspan="1">S−1+Oxaliplatin vs. capecitabine+ Oxaliplatin 2 W/cycle</td>
<td align="left" rowspan="1" colspan="1">60/61</td>
<td align="left" rowspan="1" colspan="1">65/64</td>
<td align="left" rowspan="1" colspan="1">6.2/7.2</td>
<td align="left" rowspan="1" colspan="1">12.4/13.3</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Lee<xref ref-type="bibr" rid="pone.0084230-Lee1">[15]</xref></td>
<td align="left" rowspan="1" colspan="1">2008</td>
<td align="left" rowspan="1" colspan="1">korea</td>
<td align="left" rowspan="1" colspan="1">RCT II</td>
<td align="left" rowspan="1" colspan="1">GC</td>
<td align="left" rowspan="1" colspan="1">S−1 vs. Capecitabine 4 W/cycle</td>
<td align="left" rowspan="1" colspan="1">71/71</td>
<td align="left" rowspan="1" colspan="1">45/46</td>
<td align="left" rowspan="1" colspan="1">4.2/4.7</td>
<td align="left" rowspan="1" colspan="1">8.1/9.5</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Seol<xref ref-type="bibr" rid="pone.0084230-Seol1">[17]</xref></td>
<td align="left" rowspan="1" colspan="1">2009</td>
<td align="left" rowspan="1" colspan="1">korea</td>
<td align="left" rowspan="1" colspan="1">Retrospective</td>
<td align="left" rowspan="1" colspan="1">GC</td>
<td align="left" rowspan="1" colspan="1">S−1+Cisplatin vs. capecitabine+Cisplatin 2 W/cycle</td>
<td align="left" rowspan="1" colspan="1">73/74</td>
<td align="left" rowspan="1" colspan="1">32/40</td>
<td align="left" rowspan="1" colspan="1">5.4/5.9</td>
<td align="left" rowspan="1" colspan="1">9.6/10.8</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Shitara<xref ref-type="bibr" rid="pone.0084230-Shitara1">[18]</xref></td>
<td align="left" rowspan="1" colspan="1">2012</td>
<td align="left" rowspan="1" colspan="1">Japan</td>
<td align="left" rowspan="1" colspan="1">Retrospective</td>
<td align="left" rowspan="1" colspan="1">GC</td>
<td align="left" rowspan="1" colspan="1">S−1+cisplatin vs. Capecitabine+cisplatin 4 W/cycle</td>
<td align="left" rowspan="1" colspan="1">61/65</td>
<td align="left" rowspan="1" colspan="1">50/26</td>
<td align="left" rowspan="1" colspan="1">5.8/5.2</td>
<td align="left" rowspan="1" colspan="1">13.8/13.5</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Zang<xref ref-type="bibr" rid="pone.0084230-Zang1">[25]</xref></td>
<td align="left" rowspan="1" colspan="1">2012</td>
<td align="left" rowspan="1" colspan="1">korea</td>
<td align="left" rowspan="1" colspan="1">RCT II (Abstract)</td>
<td align="left" rowspan="1" colspan="1">CRC</td>
<td align="left" rowspan="1" colspan="1">S−1+Oxaliplatin vs. capecitabine +Oxaliplatin 2 W/cycle</td>
<td align="left" rowspan="1" colspan="1">67</td>
<td align="left" rowspan="1" colspan="1">41/41</td>
<td align="left" rowspan="1" colspan="1">6.6/8.1</td>
<td align="left" rowspan="1" colspan="1">19/22</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Hong<xref ref-type="bibr" rid="pone.0084230-Hong1">[19]</xref></td>
<td align="left" rowspan="1" colspan="1">2012</td>
<td align="left" rowspan="1" colspan="1">korea</td>
<td align="left" rowspan="1" colspan="1">RCT III</td>
<td align="left" rowspan="1" colspan="1">CRC</td>
<td align="left" rowspan="1" colspan="1">S−1+Oxaliplatin vs. capecitabine+ Oxaliplatin 2 W/cycle</td>
<td align="left" rowspan="1" colspan="1">61/60</td>
<td align="left" rowspan="1" colspan="1">168/172</td>
<td align="left" rowspan="1" colspan="1">8.5/6.7</td>
<td align="left" rowspan="1" colspan="1">21.2/20.5</td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt101"><label/><p>GC, gastric cancer; CRC, colorectal cancer; OS, overall survival; PFS, progression-free survival; RCT: randomized controlled trial; S, S−1; C, capecitabine.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b">
<title>Efficacy comparison</title>
<sec id="s3b1">
<title>Progression-free survival (PFS) and overall survival (OS)</title>
<p>5 of the 6 studies <xref ref-type="bibr" rid="pone.0084230-Lee1">[15]</xref>, <xref ref-type="bibr" rid="pone.0084230-Kim1">[16]</xref>, <xref ref-type="bibr" rid="pone.0084230-Seol1">[17]</xref>, <xref ref-type="bibr" rid="pone.0084230-Shitara1">[18]</xref>, <xref ref-type="bibr" rid="pone.0084230-Hong1">[19]</xref> with sufficient PFS and OS data were included in the meta-analysis (<xref ref-type="fig" rid="pone-0084230-g002">Figure 2</xref>, <xref ref-type="fig" rid="pone-0084230-g003">Figure 3</xref>). Our results showed that there was no significant difference in PFS or OS between S-1-based group and capecitabine-based group (PFS: HR 0.92, 95% CI 0.78–1.09, <italic>P</italic> = 0.360, I<sup>2</sup> = 0%; OS: HR 1.01, 95% CI 0.84–1.21, <italic>P</italic> = 0.949, I<sup>2</sup> = 0.7%) (<xref ref-type="table" rid="pone-0084230-t002">Table 2</xref>).</p>
<fig id="pone-0084230-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0084230.g002</object-id><label>Figure 2</label><caption>
<title>Fixed-effects model of hazard ratio (95% confidence interval) of PFS associated with S-1-based therapy compared with capecitabine-based therapy.</title>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0084230.g002" position="float" xlink:type="simple"/></fig><fig id="pone-0084230-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0084230.g003</object-id><label>Figure 3</label><caption>
<title>Fixed-effects model of hazard ratio (95% confidence interval) of OS associated with S-1-based therapy compared with capecitabine-based therapy.</title>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0084230.g003" position="float" xlink:type="simple"/></fig><table-wrap id="pone-0084230-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0084230.t002</object-id><label>Table 2</label><caption>
<title>Hazard ratios, <italic>P</italic> value, and heterogeneity for PFS and OS in the stratified analyses.</title>
</caption><alternatives><graphic id="pone-0084230-t002-2" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0084230.t002" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Efficacy</td>
<td align="left" rowspan="1" colspan="1">n</td>
<td colspan="5" align="left" rowspan="1">PFS</td>
<td colspan="5" align="left" rowspan="1">OS</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">HR</td>
<td align="left" rowspan="1" colspan="1"><italic>P</italic></td>
<td align="left" rowspan="1" colspan="1"><italic>P</italic> <sub>H</sub></td>
<td align="left" rowspan="1" colspan="1"><italic>I</italic><sup>2</sup>/%</td>
<td align="left" rowspan="1" colspan="1">HW</td>
<td align="left" rowspan="1" colspan="1">HR</td>
<td align="left" rowspan="1" colspan="1"><italic>P</italic></td>
<td align="left" rowspan="1" colspan="1"><italic>P</italic> <sub>H</sub></td>
<td align="left" rowspan="1" colspan="1"><italic>I</italic><sup>2</sup>/%</td>
<td align="left" rowspan="1" colspan="1">HW</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>All</bold></td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">0.92(0.78,1.09)</td>
<td align="left" rowspan="1" colspan="1">0.360</td>
<td align="left" rowspan="1" colspan="1">0.652</td>
<td align="left" rowspan="1" colspan="1">0.0</td>
<td align="left" rowspan="1" colspan="1">100</td>
<td align="left" rowspan="1" colspan="1">1.01(0.84,1.21)</td>
<td align="left" rowspan="1" colspan="1">0.949</td>
<td align="left" rowspan="1" colspan="1">0.402</td>
<td align="left" rowspan="1" colspan="1">0.7</td>
<td align="left" rowspan="1" colspan="1">100</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>type</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">GC</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">1.02(0.82,1.26)</td>
<td align="left" rowspan="1" colspan="1">0.886</td>
<td align="left" rowspan="1" colspan="1">0.929</td>
<td align="left" rowspan="1" colspan="1">0.0</td>
<td align="left" rowspan="1" colspan="1">62.53</td>
<td align="left" rowspan="1" colspan="1">1.14(0.91,1.43)</td>
<td align="left" rowspan="1" colspan="1">0.271</td>
<td align="left" rowspan="1" colspan="1">0.783</td>
<td align="left" rowspan="1" colspan="1">0.0</td>
<td align="left" rowspan="1" colspan="1">62.57</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">CRC</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">0.79(0.60,1.04)</td>
<td align="left" rowspan="1" colspan="1">0.093</td>
<td align="left" rowspan="1" colspan="1">N/A</td>
<td align="left" rowspan="1" colspan="1">N/A</td>
<td align="left" rowspan="1" colspan="1">37.47</td>
<td align="left" rowspan="1" colspan="1">0.82(0.61,1.10)</td>
<td align="left" rowspan="1" colspan="1">0.187</td>
<td align="left" rowspan="1" colspan="1">N/A</td>
<td align="left" rowspan="1" colspan="1">N/A</td>
<td align="left" rowspan="1" colspan="1">37.43</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>age</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">&lt;70</td>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">0.89(0.73,1.09)</td>
<td align="left" rowspan="1" colspan="1">0.274</td>
<td align="left" rowspan="1" colspan="1">0.409</td>
<td align="left" rowspan="1" colspan="1">0.0</td>
<td align="left" rowspan="1" colspan="1">68.21</td>
<td align="left" rowspan="1" colspan="1">0.92(0.75,1.14)</td>
<td align="left" rowspan="1" colspan="1">0.456</td>
<td align="left" rowspan="1" colspan="1">0.511</td>
<td align="left" rowspan="1" colspan="1">0.0</td>
<td align="left" rowspan="1" colspan="1">71.54</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">≥70</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">1.00(0.74,1.34)</td>
<td align="left" rowspan="1" colspan="1">0.984</td>
<td align="left" rowspan="1" colspan="1">0.578</td>
<td align="left" rowspan="1" colspan="1">0.0</td>
<td align="left" rowspan="1" colspan="1">31.79</td>
<td align="left" rowspan="1" colspan="1">1.25(0.89,1.76)</td>
<td align="left" rowspan="1" colspan="1">0.193</td>
<td align="left" rowspan="1" colspan="1">0.510</td>
<td align="left" rowspan="1" colspan="1">0.0</td>
<td align="left" rowspan="1" colspan="1">28.46</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>combine</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Oxa</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">0.88(0.70,1.10)</td>
<td align="left" rowspan="1" colspan="1">0.250</td>
<td align="left" rowspan="1" colspan="1">0.199</td>
<td align="left" rowspan="1" colspan="1">39.3</td>
<td align="left" rowspan="1" colspan="1">67.38</td>
<td align="left" rowspan="1" colspan="1">0.91(0.72,1.15)</td>
<td align="left" rowspan="1" colspan="1">0.425</td>
<td align="left" rowspan="1" colspan="1">0.261</td>
<td align="left" rowspan="1" colspan="1">20.8</td>
<td align="left" rowspan="1" colspan="1">71.21</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Cis</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">0.93(0.77,1.11)</td>
<td align="left" rowspan="1" colspan="1">0.835</td>
<td align="left" rowspan="1" colspan="1">0.725</td>
<td align="left" rowspan="1" colspan="1">0.0</td>
<td align="left" rowspan="1" colspan="1">32.62</td>
<td align="left" rowspan="1" colspan="1">1.20(0.83,1.73)</td>
<td align="left" rowspan="1" colspan="1">0.336</td>
<td align="left" rowspan="1" colspan="1">0.335</td>
<td align="left" rowspan="1" colspan="1">0.0</td>
<td align="left" rowspan="1" colspan="1">28.79</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>study</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">RCT</td>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">0.89(0.73,1.08)</td>
<td align="left" rowspan="1" colspan="1">0.230</td>
<td align="left" rowspan="1" colspan="1">0.429</td>
<td align="left" rowspan="1" colspan="1">0.0</td>
<td align="left" rowspan="1" colspan="1">72.83</td>
<td align="left" rowspan="1" colspan="1">0.95(0.77,1.17)</td>
<td align="left" rowspan="1" colspan="1">0.638</td>
<td align="left" rowspan="1" colspan="1">0.376</td>
<td align="left" rowspan="1" colspan="1">0.0</td>
<td align="left" rowspan="1" colspan="1">75.73</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">RS</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">1.04(0.75,1.43)</td>
<td align="left" rowspan="1" colspan="1">0.835</td>
<td align="left" rowspan="1" colspan="1">0.725</td>
<td align="left" rowspan="1" colspan="1">0.0</td>
<td align="left" rowspan="1" colspan="1">27.17</td>
<td align="left" rowspan="1" colspan="1">1.01(0.84,1.21)</td>
<td align="left" rowspan="1" colspan="1">0.336</td>
<td align="left" rowspan="1" colspan="1">0.335</td>
<td align="left" rowspan="1" colspan="1">0.0</td>
<td align="left" rowspan="1" colspan="1">24.27</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>schedule</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2 week</td>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">0.92(0.75,1.12)</td>
<td align="left" rowspan="1" colspan="1">0.400</td>
<td align="left" rowspan="1" colspan="1">0.299</td>
<td align="left" rowspan="1" colspan="1">17.2</td>
<td align="left" rowspan="1" colspan="1">71.20</td>
<td align="left" rowspan="1" colspan="1">0.98(0.80,1.22)</td>
<td align="left" rowspan="1" colspan="1">0.878</td>
<td align="left" rowspan="1" colspan="1">0.155</td>
<td align="left" rowspan="1" colspan="1">46.4</td>
<td align="left" rowspan="1" colspan="1">72.81</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">4 week</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">0.94(0.69,1.29)</td>
<td align="left" rowspan="1" colspan="1">0.702</td>
<td align="left" rowspan="1" colspan="1">0.870</td>
<td align="left" rowspan="1" colspan="1">0.0</td>
<td align="left" rowspan="1" colspan="1">28.80</td>
<td align="left" rowspan="1" colspan="1">1.07(0.76,1.51)</td>
<td align="left" rowspan="1" colspan="1">0.707</td>
<td align="left" rowspan="1" colspan="1">0.711</td>
<td align="left" rowspan="1" colspan="1">0.0</td>
<td align="left" rowspan="1" colspan="1">27.19</td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt102"><label/><p>HR, hazard ratio; <italic>P</italic><sub>H</sub>, heterogeneity <italic>P</italic>; GC, gastric cancer; CRC, colorectal cancer; OS, overall survival; PFS, progression-free survival; RCT, randomized controlled trial; RS, Retrospective study;</p></fn></table-wrap-foot></table-wrap>
<p>In the subgroup analysis by cancer types, no significant difference was observed in PFS or OS between S-1-based and capecitabine-based regimens in GC group (PFS: HR 1.02, 95% CI 0.82–1.26, <italic>P</italic> = 0.886, I<sup>2</sup> = 0%; OS: HR 1.14, 95% CI 0.91–1.43, <italic>P</italic> = 0.271, I<sup>2</sup> = 0%). Similar results were observed in CRC group. Additionally, in the stratified analysis by age, combined medicine, treatment schedule and trial type, the results of predefined clinical subgroup analyses for PFS and OS were generally consistent with the results found in all patients (statistically not significant). Besides, there was no heterogeneity observed (<xref ref-type="table" rid="pone-0084230-t002">Table 2</xref>).</p>
</sec><sec id="s3b2">
<title>Objective response rate (ORR) and disease control rate (DCR)</title>
<p>All six studies reported ORR and DCR data. The ORR was 40.2% (146 of 363 patients) in the S-1-based group and 38.3% (133 of 347 patients) in the capecitabine-based group. The DCR was 78.5% (285 of 363 patients) in the S-1-based group and 76.4% (265 of 347 patients) in the capecitabine-based group. Though the comparison of S-1 with capecitabine showed that S-1-based group had a slightly higher ORR and DCR, the pooled RR for overall response rate and disease control rate showed no statistically significant difference between the two groups (ORR: HR 1.04, 95% CI 0.87–1.25, <italic>P</italic> = 0.683, I<sup>2</sup> = 30.7%; DCR: HR 1.02, 95% CI 0.94–1.10, <italic>P</italic> = 0.639, I<sup>2</sup> = 0%) (<xref ref-type="fig" rid="pone-0084230-g004">Figure 4</xref>, <xref ref-type="fig" rid="pone-0084230-g005">Figure 5</xref>). In the subgroup analysis by combined medicine, no significant difference was observed in ORR or DCR between S-1 combined oxaliplatin and capecitabine combined oxaliplatin regimens. Similar results were observed between S-1 combined cisplatin and capecitabine combined cisplatin regimens, which indicated that S-1 was comparable to capecitabine in the two most commonly used regimens in gastrointestinal cancers (<xref ref-type="table" rid="pone-0084230-t003">Table 3</xref>).</p>
<fig id="pone-0084230-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0084230.g004</object-id><label>Figure 4</label><caption>
<title>Fixed-effects model of hazard ratio (95% confidence interval) of ORR associated with S-1-based therapy compared with capecitabine-based therapy.</title>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0084230.g004" position="float" xlink:type="simple"/></fig><fig id="pone-0084230-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0084230.g005</object-id><label>Figure 5</label><caption>
<title>Fixed-effects model of hazard ratio (95% confidence interval) of DCR associated with S-1-based therapy compared with capecitabine-based therapy.</title>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0084230.g005" position="float" xlink:type="simple"/></fig><table-wrap id="pone-0084230-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0084230.t003</object-id><label>Table 3</label><caption>
<title>Hazard ratios, <italic>P</italic> value, and heterogeneity for ORR and DCR in the stratified analyses.</title>
</caption><alternatives><graphic id="pone-0084230-t003-3" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0084230.t003" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Efficacy</td>
<td align="left" rowspan="1" colspan="1">n</td>
<td colspan="5" align="left" rowspan="1">ORR</td>
<td colspan="5" align="left" rowspan="1">DCR</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">RR</td>
<td align="left" rowspan="1" colspan="1"><italic>P</italic></td>
<td align="left" rowspan="1" colspan="1"><italic>P</italic> <sub>H</sub></td>
<td align="left" rowspan="1" colspan="1"><italic>I</italic><sup>2</sup>/%</td>
<td align="left" rowspan="1" colspan="1">HW</td>
<td align="left" rowspan="1" colspan="1">RR</td>
<td align="left" rowspan="1" colspan="1"><italic>P</italic></td>
<td align="left" rowspan="1" colspan="1"><italic>P</italic> <sub>H</sub></td>
<td align="left" rowspan="1" colspan="1"><italic>I</italic><sup>2</sup>/%</td>
<td align="left" rowspan="1" colspan="1">HW</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>All</bold></td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1">1.04(0.87,1.25)</td>
<td align="left" rowspan="1" colspan="1">0.683</td>
<td align="left" rowspan="1" colspan="1">0.205</td>
<td align="left" rowspan="1" colspan="1">30.7</td>
<td align="left" rowspan="1" colspan="1">100</td>
<td align="left" rowspan="1" colspan="1">1.02(0.94,1.10)</td>
<td align="left" rowspan="1" colspan="1">0.639</td>
<td align="left" rowspan="1" colspan="1">0.423</td>
<td align="left" rowspan="1" colspan="1">0.0</td>
<td align="left" rowspan="1" colspan="1">100</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>type</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">GC</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">0.88(0.66,1.16)</td>
<td align="left" rowspan="1" colspan="1">0.363</td>
<td align="left" rowspan="1" colspan="1">0.796</td>
<td align="left" rowspan="1" colspan="1">0.0</td>
<td align="left" rowspan="1" colspan="1">46.12</td>
<td align="left" rowspan="1" colspan="1">0.99(0.86,1.14)</td>
<td align="left" rowspan="1" colspan="1">0.898</td>
<td align="left" rowspan="1" colspan="1">0.469</td>
<td align="left" rowspan="1" colspan="1">0.0</td>
<td align="left" rowspan="1" colspan="1">40.70</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">CRC</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">1.18(0.93,1.50)</td>
<td align="left" rowspan="1" colspan="1">0.185</td>
<td align="left" rowspan="1" colspan="1">0.057</td>
<td align="left" rowspan="1" colspan="1">72.3</td>
<td align="left" rowspan="1" colspan="1">53.88</td>
<td align="left" rowspan="1" colspan="1">1.04(0.95,1.13)</td>
<td align="left" rowspan="1" colspan="1">0.416</td>
<td align="left" rowspan="1" colspan="1">0.136</td>
<td align="left" rowspan="1" colspan="1">55.1</td>
<td align="left" rowspan="1" colspan="1">59.30</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>age</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">&lt;70</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">1.08(0.89,1.32)</td>
<td align="left" rowspan="1" colspan="1">0.438</td>
<td align="left" rowspan="1" colspan="1">0.145</td>
<td align="left" rowspan="1" colspan="1">44.5</td>
<td align="left" rowspan="1" colspan="1">79.43</td>
<td align="left" rowspan="1" colspan="1">1.04(0.96,1.12)</td>
<td align="left" rowspan="1" colspan="1">0.330</td>
<td align="left" rowspan="1" colspan="1">0.468</td>
<td align="left" rowspan="1" colspan="1">0.0</td>
<td align="left" rowspan="1" colspan="1">81.75</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">≥70</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">0.87(0.55,1.37)</td>
<td align="left" rowspan="1" colspan="1">0.546</td>
<td align="left" rowspan="1" colspan="1">0.314</td>
<td align="left" rowspan="1" colspan="1">1.2</td>
<td align="left" rowspan="1" colspan="1">20.57</td>
<td align="left" rowspan="1" colspan="1">0.93(0.72,1.20)</td>
<td align="left" rowspan="1" colspan="1">0.581</td>
<td align="left" rowspan="1" colspan="1">0.213</td>
<td align="left" rowspan="1" colspan="1">35.6</td>
<td align="left" rowspan="1" colspan="1">18.25</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>combine</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Oxa</td>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">1.11(0.90,1.38)</td>
<td align="left" rowspan="1" colspan="1">0.330</td>
<td align="left" rowspan="1" colspan="1">0.094</td>
<td align="left" rowspan="1" colspan="1">57.8</td>
<td align="left" rowspan="1" colspan="1">76.55</td>
<td align="left" rowspan="1" colspan="1">1.05(0.97,1.13)</td>
<td align="left" rowspan="1" colspan="1">0.267</td>
<td align="left" rowspan="1" colspan="1">0.330</td>
<td align="left" rowspan="1" colspan="1">9.9</td>
<td align="left" rowspan="1" colspan="1">83.75</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Cis</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">0.77(0.51,1.18)</td>
<td align="left" rowspan="1" colspan="1">0.227</td>
<td align="left" rowspan="1" colspan="1">0.607</td>
<td align="left" rowspan="1" colspan="1">0.0</td>
<td align="left" rowspan="1" colspan="1">23.45</td>
<td align="left" rowspan="1" colspan="1">0.86(0.64,1.14)</td>
<td align="left" rowspan="1" colspan="1">0.292</td>
<td align="left" rowspan="1" colspan="1">0.331</td>
<td align="left" rowspan="1" colspan="1">0.0</td>
<td align="left" rowspan="1" colspan="1">16.25</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>study</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">RCT</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">1.11(0.91,1.37)</td>
<td align="left" rowspan="1" colspan="1">0.309</td>
<td align="left" rowspan="1" colspan="1">0.192</td>
<td align="left" rowspan="1" colspan="1">36.7</td>
<td align="left" rowspan="1" colspan="1">78.61</td>
<td align="left" rowspan="1" colspan="1">1.05(0.97,1.13)</td>
<td align="left" rowspan="1" colspan="1">0.250</td>
<td align="left" rowspan="1" colspan="1">0.533</td>
<td align="left" rowspan="1" colspan="1">0.0</td>
<td align="left" rowspan="1" colspan="1">85.53</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">RS</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">0.77(0.51,1.18)</td>
<td align="left" rowspan="1" colspan="1">0.227</td>
<td align="left" rowspan="1" colspan="1">0.607</td>
<td align="left" rowspan="1" colspan="1">0.0</td>
<td align="left" rowspan="1" colspan="1">21.39</td>
<td align="left" rowspan="1" colspan="1">0.86(0.64,1.14)</td>
<td align="left" rowspan="1" colspan="1">0.292</td>
<td align="left" rowspan="1" colspan="1">0.331</td>
<td align="left" rowspan="1" colspan="1">0.0</td>
<td align="left" rowspan="1" colspan="1">14.47</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>schedule</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2 week</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">1.05(0.86,1.29)</td>
<td align="left" rowspan="1" colspan="1">0.622</td>
<td align="left" rowspan="1" colspan="1">0.080</td>
<td align="left" rowspan="1" colspan="1">55.6</td>
<td align="left" rowspan="1" colspan="1">81.66</td>
<td align="left" rowspan="1" colspan="1">1.02(0.94,1.10)</td>
<td align="left" rowspan="1" colspan="1">0.673</td>
<td align="left" rowspan="1" colspan="1">0.183</td>
<td align="left" rowspan="1" colspan="1">38.2</td>
<td align="left" rowspan="1" colspan="1">81.79</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">4 week</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">0.98(0.63,1.52)</td>
<td align="left" rowspan="1" colspan="1">0.931</td>
<td align="left" rowspan="1" colspan="1">0.577</td>
<td align="left" rowspan="1" colspan="1">0.0</td>
<td align="left" rowspan="1" colspan="1">18.34</td>
<td align="left" rowspan="1" colspan="1">1.02(0.83,1.27)</td>
<td align="left" rowspan="1" colspan="1">0.834</td>
<td align="left" rowspan="1" colspan="1">0.706</td>
<td align="left" rowspan="1" colspan="1">0.0</td>
<td align="left" rowspan="1" colspan="1">18.21</td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt103"><label/><p>HR, hazard ratio; <italic>P</italic><sub>H</sub>, heterogeneity <italic>P</italic>; GC, gastric cancer; CRC, colorectal cancer; ORR, objective response rate; DCR, disease control rate; RCT, randomized controlled trial; RS, Retrospective study.</p></fn></table-wrap-foot></table-wrap>
<p>Additionally, in the stratified analysis by age, cancer type, treatment schedule and trial type, the results of ORR and DCR were generally consistent with the results found in all patients (statistically not significant). Besides, there was no heterogeneity observed (<xref ref-type="table" rid="pone-0084230-t003">Table 3</xref>).</p>
</sec></sec><sec id="s3c">
<title>Safety</title>
<p>Safety-related information was reported in all the 6 studies. The common AEs were anaemia, neutropenia, thrombocytopenia, asthenia, anorexia, nausea and neuropathy, which were experienced by nearly half of the patients both in S-1-based and capecitabine-based group. Anorexia was the most common AE both in the two groups (67% in S-1-based group and 59% in capecitabine-based group) and happened slightly more frequently in S-1-based regimens (RR 1.13, 95% CI 1.01–1.27, <italic>P</italic> = 0.034). As anticipated, the frequency of hand foot syndrome (HFS) was 10% in S-1-based group and 33% in capecitabine-based group, with a significant difference between them (RR 0.30, 95% CI 0.22–0.42, <italic>P</italic>&lt;0.001).</p>
<p>As anticipated, the frequency of hand foot syndrome (HFS) in capecitabine-based group was significantly more common than in S-1-based group (10% in S-1-based, 33% in capecitabine-based, RR 0.30, 95% CI 0.22–0.42, <italic>P</italic>&lt;0.001). Similar results were observed in the two groups when comparing the Grade 3 or 4 HFS (0.3% in S-1-based, 3% in capecitabine-based, RR 0.23, 95% CI 0.07–0.78, <italic>P</italic> = 0.019). No significant differences regarding the occurrence of other AEs at any grade was found between the two groups (<xref ref-type="table" rid="pone-0084230-t004">Table 4</xref>).</p>
<table-wrap id="pone-0084230-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0084230.t004</object-id><label>Table 4</label><caption>
<title>Summary of adverse events.</title>
</caption><alternatives><graphic id="pone-0084230-t004-4" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0084230.t004" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">All grade AEs</td>
<td align="left" rowspan="1" colspan="1">N</td>
<td align="left" rowspan="1" colspan="1">S-1 N/T</td>
<td align="left" rowspan="1" colspan="1">%</td>
<td align="left" rowspan="1" colspan="1">Capecitabine N/T</td>
<td align="left" rowspan="1" colspan="1">%</td>
<td align="left" rowspan="1" colspan="1">RR(95%CI)</td>
<td align="left" rowspan="1" colspan="1"><italic>P</italic> value</td>
<td align="left" rowspan="1" colspan="1">Grade 3–4 AEs</td>
<td align="left" rowspan="1" colspan="1">N</td>
<td align="left" rowspan="1" colspan="1">S-1 N/T</td>
<td align="left" rowspan="1" colspan="1">%</td>
<td align="left" rowspan="1" colspan="1">Capecitabine N/T</td>
<td align="left" rowspan="1" colspan="1">%</td>
<td align="left" rowspan="1" colspan="1">RR(95%CI)</td>
<td align="left" rowspan="1" colspan="1"><italic>P</italic> value</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Anaemia</td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1">206/399</td>
<td align="left" rowspan="1" colspan="1">51.6</td>
<td align="left" rowspan="1" colspan="1">178/381</td>
<td align="left" rowspan="1" colspan="1">46.7</td>
<td align="left" rowspan="1" colspan="1">1.10(0.99,1.22)</td>
<td align="left" rowspan="1" colspan="1">0.090</td>
<td align="left" rowspan="1" colspan="1">Anaemia</td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1">35/399</td>
<td align="left" rowspan="1" colspan="1">8.8</td>
<td align="left" rowspan="1" colspan="1">23/381</td>
<td align="left" rowspan="1" colspan="1">6.0</td>
<td align="left" rowspan="1" colspan="1">1.39(0.85,2.28)</td>
<td align="left" rowspan="1" colspan="1">0.195</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Neutropenia</td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1">183/399</td>
<td align="left" rowspan="1" colspan="1">45.9</td>
<td align="left" rowspan="1" colspan="1">172/381</td>
<td align="left" rowspan="1" colspan="1">45.1</td>
<td align="left" rowspan="1" colspan="1">0.98(0.84,1.14)</td>
<td align="left" rowspan="1" colspan="1">0.767</td>
<td align="left" rowspan="1" colspan="1">Neutropenia</td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1">76/399</td>
<td align="left" rowspan="1" colspan="1">19.0</td>
<td align="left" rowspan="1" colspan="1">54/381</td>
<td align="left" rowspan="1" colspan="1">14.2</td>
<td align="left" rowspan="1" colspan="1">0.92(0.45,1.86)</td>
<td align="left" rowspan="1" colspan="1">0.806</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Leukopenia</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">75/326</td>
<td align="left" rowspan="1" colspan="1">23.0</td>
<td align="left" rowspan="1" colspan="1">65/300</td>
<td align="left" rowspan="1" colspan="1">21.7</td>
<td align="left" rowspan="1" colspan="1">0.95(0.75,1.21)</td>
<td align="left" rowspan="1" colspan="1">0.697</td>
<td align="left" rowspan="1" colspan="1">Leukopenia</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">10/326</td>
<td align="left" rowspan="1" colspan="1">3.1</td>
<td align="left" rowspan="1" colspan="1">5/300</td>
<td align="left" rowspan="1" colspan="1">1.7</td>
<td align="left" rowspan="1" colspan="1">1.70(0.59,4.91)</td>
<td align="left" rowspan="1" colspan="1">0.328</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Thrombocytopenia</td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1">183/399</td>
<td align="left" rowspan="1" colspan="1">45.9</td>
<td align="left" rowspan="1" colspan="1">151/381</td>
<td align="left" rowspan="1" colspan="1">39.6</td>
<td align="left" rowspan="1" colspan="1">1.09(0.82,1.45)</td>
<td align="left" rowspan="1" colspan="1">0.570</td>
<td align="left" rowspan="1" colspan="1">Thrombocytopenia</td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1">56/399</td>
<td align="left" rowspan="1" colspan="1">14.0</td>
<td align="left" rowspan="1" colspan="1">33/381</td>
<td align="left" rowspan="1" colspan="1">8.7</td>
<td align="left" rowspan="1" colspan="1">1.32(0.55,3.14)</td>
<td align="left" rowspan="1" colspan="1">0.533</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Asthenia</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">183/358</td>
<td align="left" rowspan="1" colspan="1">51.1</td>
<td align="left" rowspan="1" colspan="1">167/340</td>
<td align="left" rowspan="1" colspan="1">49.1</td>
<td align="left" rowspan="1" colspan="1">1.07(0.93,1.24)</td>
<td align="left" rowspan="1" colspan="1">0.365</td>
<td align="left" rowspan="1" colspan="1">Asthenia</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">19/358</td>
<td align="left" rowspan="1" colspan="1">5.3</td>
<td align="left" rowspan="1" colspan="1">20/340</td>
<td align="left" rowspan="1" colspan="1">5.9</td>
<td align="left" rowspan="1" colspan="1">0.92(0.50,1.69)</td>
<td align="left" rowspan="1" colspan="1">0.788</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Anorexia</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">239/358</td>
<td align="left" rowspan="1" colspan="1">66.8</td>
<td align="left" rowspan="1" colspan="1">202/340</td>
<td align="left" rowspan="1" colspan="1">59.4</td>
<td align="left" rowspan="1" colspan="1">1.13(1.01,1.27)</td>
<td align="left" rowspan="1" colspan="1">0.034</td>
<td align="left" rowspan="1" colspan="1">Anorexia</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">31/358</td>
<td align="left" rowspan="1" colspan="1">8.7</td>
<td align="left" rowspan="1" colspan="1">16/340</td>
<td align="left" rowspan="1" colspan="1">4.7</td>
<td align="left" rowspan="1" colspan="1">1.67(0.94,2.98)</td>
<td align="left" rowspan="1" colspan="1">0.081</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Nausea</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">193/358</td>
<td align="left" rowspan="1" colspan="1">53.9</td>
<td align="left" rowspan="1" colspan="1">169/340</td>
<td align="left" rowspan="1" colspan="1">49.7</td>
<td align="left" rowspan="1" colspan="1">1.08(0.93,1.24)</td>
<td align="left" rowspan="1" colspan="1">0.322</td>
<td align="left" rowspan="1" colspan="1">Nausea</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">19/358</td>
<td align="left" rowspan="1" colspan="1">5.3</td>
<td align="left" rowspan="1" colspan="1">14/340</td>
<td align="left" rowspan="1" colspan="1">4.1</td>
<td align="left" rowspan="1" colspan="1">1.17(0.60,2.28)</td>
<td align="left" rowspan="1" colspan="1">0.643</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Vomiting</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">116/358</td>
<td align="left" rowspan="1" colspan="1">32.4</td>
<td align="left" rowspan="1" colspan="1">108/364</td>
<td align="left" rowspan="1" colspan="1">29.7</td>
<td align="left" rowspan="1" colspan="1">1.09(0.88,1.35)</td>
<td align="left" rowspan="1" colspan="1">0.440</td>
<td align="left" rowspan="1" colspan="1">Vomiting</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">8/358</td>
<td align="left" rowspan="1" colspan="1">2.2</td>
<td align="left" rowspan="1" colspan="1">11/364</td>
<td align="left" rowspan="1" colspan="1">3.0</td>
<td align="left" rowspan="1" colspan="1">0.77(0.32,1.83)</td>
<td align="left" rowspan="1" colspan="1">0.554</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Diarrhoea</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">128/358</td>
<td align="left" rowspan="1" colspan="1">35.8</td>
<td align="left" rowspan="1" colspan="1">109/340</td>
<td align="left" rowspan="1" colspan="1">32.1</td>
<td align="left" rowspan="1" colspan="1">1.13(0.91,1.39)</td>
<td align="left" rowspan="1" colspan="1">0.265</td>
<td align="left" rowspan="1" colspan="1">Diarrhoea</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">25/356</td>
<td align="left" rowspan="1" colspan="1">7.0</td>
<td align="left" rowspan="1" colspan="1">16/340</td>
<td align="left" rowspan="1" colspan="1">4.7</td>
<td align="left" rowspan="1" colspan="1">1.49(0.81,2.74)</td>
<td align="left" rowspan="1" colspan="1">0.206</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Stomatitis</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">88/293</td>
<td align="left" rowspan="1" colspan="1">30.0</td>
<td align="left" rowspan="1" colspan="1">73/276</td>
<td align="left" rowspan="1" colspan="1">26.4</td>
<td align="left" rowspan="1" colspan="1">0.91(0.40,2.08)</td>
<td align="left" rowspan="1" colspan="1">0.829</td>
<td align="left" rowspan="1" colspan="1">Stomatitis</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">3/293</td>
<td align="left" rowspan="1" colspan="1">1.0</td>
<td align="left" rowspan="1" colspan="1">1/276</td>
<td align="left" rowspan="1" colspan="1">0.4</td>
<td align="left" rowspan="1" colspan="1">1.51(0.29,7.78)</td>
<td align="left" rowspan="1" colspan="1">0.622</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Neuropathy</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">182/307</td>
<td align="left" rowspan="1" colspan="1">59.3</td>
<td align="left" rowspan="1" colspan="1">184/311</td>
<td align="left" rowspan="1" colspan="1">59.2</td>
<td align="left" rowspan="1" colspan="1">0.98(0.87,1.10)</td>
<td align="left" rowspan="1" colspan="1">0.709</td>
<td align="left" rowspan="1" colspan="1">Neuropathy</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">19/307</td>
<td align="left" rowspan="1" colspan="1">6.2</td>
<td align="left" rowspan="1" colspan="1">14/311</td>
<td align="left" rowspan="1" colspan="1">4.5</td>
<td align="left" rowspan="1" colspan="1">1.34(0.69,2.61)</td>
<td align="left" rowspan="1" colspan="1">0.395</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Hand foot syndrome</td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1">40/399</td>
<td align="left" rowspan="1" colspan="1">10.0</td>
<td align="left" rowspan="1" colspan="1">127/381</td>
<td align="left" rowspan="1" colspan="1">33.3</td>
<td align="left" rowspan="1" colspan="1">0.30(0.22,0.42)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
<td align="left" rowspan="1" colspan="1">Hand foot syndrome</td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1">1/399</td>
<td align="left" rowspan="1" colspan="1">0.3</td>
<td align="left" rowspan="1" colspan="1">12/381</td>
<td align="left" rowspan="1" colspan="1">3.1</td>
<td align="left" rowspan="1" colspan="1">0.23(0.07,0.78)</td>
<td align="left" rowspan="1" colspan="1">0.019</td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt104"><label/><p>AEs, adverse events; CI, confidence interval; N/T, the number of adverse reactions/the total number of patients; RR, risk ratio.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3d">
<title>Publication bias</title>
<p>Begg's funnel plot and Egger's test were performed to assess the publication bias of literatures. The shapes of the funnel plots did not reveal any evidence of obvious asymmetry (<italic>P</italic> = 0.806 for PFS, <italic>P</italic> = 0.462 for OS, <xref ref-type="fig" rid="pone-0084230-g006">Figure 6</xref>). Then, Egger's test was used to provide statistical evidence of funnel plot symmetry. The results still did not suggest any evidence of publication bias (<italic>P</italic> = 0.098 for PFS, <italic>P</italic> = 0.122 for OS, respectively).</p>
<fig id="pone-0084230-g006" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0084230.g006</object-id><label>Figure 6</label><caption>
<title>Begg's funnel plot of publication bias test.</title>
<p>(A) PFS; (B) OS. Each point represents a separate study for the indicated association. Log (OR), natural logarithm of OR. Horizontal line, mean effect size.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0084230.g006" position="float" xlink:type="simple"/></fig></sec></sec><sec id="s4">
<title>Discussion</title>
<p>This is the first meta-analysis to estimate the relative efficacy and safety of two new oral fluoropyrimidines, S-1 and capecitabine. Our results indicated that S-1-based and capecitabine-based regimens showed very similar efficacy in terms of PFS, OS, ORR and DCR. There was also no significant difference in toxicity between regimens other than mild more hand–foot syndrome in capecitabine-based regimens. In conclusion, both the S-1-based and capecitabine-based regimens are equally active and well tolerated, and have the potential of backbone chemotherapy regimen in further studies of gastrointestinal cancers.</p>
<p>After years of argument about the utility of chemotherapy for gastrointestinal cancer, extensive clinical research contributed to the optimization of fluoropyrimidines administration, with oral S-1 and capecitabine emerging as the standard therapy in advanced gastrointestinal cancer. Since S-1 and capecitabine offered the advantages of simplicity and convenience over the traditional 5-FU, they have opened new perspectives for improving survival of patients with gastrointestinal cancer.</p>
<p>The findings of the Japan Clinical Oncology Group (JCOG) 9912 trial that compared fluorouracil alone versus irinotecan plus cisplatin versus S-1 alone, suggested that S-1 was no worse than fluorouracil or irinotecan plus cisplatin in advanced gastric cancer (AGC)<xref ref-type="bibr" rid="pone.0084230-Boku1">[26]</xref>. Additionally, S-1 combined with cisplatin (SP), showed superior efficacy to S-1 alone in the SPIRITS trial <xref ref-type="bibr" rid="pone.0084230-Koizumi1">[6]</xref> and has now became the standard chemotherapy for AGC in Japan. However, in a large, non-Japanese, phase III trial (the First-Line Advanced Gastric Cancer Study; FLAGS trial), SP did not show superiority compared with 5-FU plus cisplatin, although exploratory analysis demonstrated significant non-inferiority with fewer toxic effects <xref ref-type="bibr" rid="pone.0084230-Ajani1">[13]</xref>. Kang et al. evaluated capecitabine plus cisplatin (XP) versus 5-FU plus cisplatin, showing significant non-inferiority in the median PFS showed <xref ref-type="bibr" rid="pone.0084230-Kang1">[7]</xref>. In the REAL-2 study, statistical non-inferiority for OS was achieved for comparisons of capecitabine versus 5-FU <xref ref-type="bibr" rid="pone.0084230-Cunningham2">[27]</xref>. Additionally, meta-analysis of these two trials showed that OS was superior in the capecitabine-based regimens than 5-FU-based regimens <xref ref-type="bibr" rid="pone.0084230-Okines1">[14]</xref>. On the basis of these results, XP regimen is now considered one of the standard chemotherapy for AGC, and recently two global studies of molecular targeting agents each adopted XP regimen as the reference arm <xref ref-type="bibr" rid="pone.0084230-Bang1">[28]</xref>, <xref ref-type="bibr" rid="pone.0084230-Ohtsu1">[29]</xref>.</p>
<p>Recently, several studies had focused on the difference between S-1-based and capecitabine-based regimens. A previous phase II study of capecitabine monotherapy in Japan showed an ORR of 23% <xref ref-type="bibr" rid="pone.0084230-Sakamoto1">[30]</xref>, which seemed to be lower than that of S-1 <xref ref-type="bibr" rid="pone.0084230-Sakata1">[31]</xref>. However, Lee et al. <xref ref-type="bibr" rid="pone.0084230-Lee1">[15]</xref> performed a randomized phase II study of monotherapy of S-1 and capecitabine for elderly AGC patients, and reported similar efficacies and safety for them. In the study by Hong in colorectal cancer, S-1 combined with oxaliplatin (SOX) was non-inferior to standard capecitabine combined with oxaliplatin (CapeOX) in terms of PFS, which is still regarded as one of the reference doublet cytotoxic chemotherapy in many countries, and showed improvements in ORR, incidences of grade 3–4 neutropenia, thrombocytopenia, and diarrhoea were higher in the SOX group than in the CapeOX group<xref ref-type="bibr" rid="pone.0084230-Hong1">[19]</xref>. The limited number of trials, with dissimilar criteria, methodologies, and evaluation standards used, had likely resulted in inconsistent outcomes. To comprehensively assess the advantages and disadvantages of S-1-based and capecitabine-based therapy for patients with gastrointestinal cancer, we undertook a meta-analysis of published data from all the correlated studies.</p>
<p>Our results showed that there was no significant difference in terms of PFS, OS, ORR or DCR between S-1-based regimens and capecitabine-based regimens, and sharing very similar efficacy. In the subgroup analysis by cancer types, no significant difference was observed in PFS or OS between the two groups which were consistent with the included studies. When comparing the efficacy differed by age, Lee et al. have reported similar efficacies and safety for elderly AGC patients between the two regimens <xref ref-type="bibr" rid="pone.0084230-Lee1">[15]</xref>. Similar results were observed not only in the elderly group, but also in the younger group. Oral fluoropyrimidines combined with cisplatin or oxaliplatin were most common regimes in the gastrointestinal cancers. Recently research focused on these regimens demonstrated SOX and CAPOX, SP and XP were equally active and well tolerated in advanced gastrointestinal cancers <xref ref-type="bibr" rid="pone.0084230-Kim1">[16]</xref>, <xref ref-type="bibr" rid="pone.0084230-Seol1">[17]</xref>, <xref ref-type="bibr" rid="pone.0084230-Shitara1">[18]</xref>, <xref ref-type="bibr" rid="pone.0084230-Hong1">[19]</xref>. In the subgroup analysis by combined medicine in our meta-analysis, S-1 showed the similar efficacy with capecitabine when combined with cisplatin or oxaliplatin in GC and CRC.</p>
<p>With regard to safety profile, our analysis suggested that the profile of toxicity associated with both S-1-based therapy and capecitabine-based therapy was equivalent, although a higher incidence of hand–foot syndrome was documented in the capecitabine -based group. Grade 1 or 2 hand–foot syndrome was generally manageable with topical ointments or adequate dose reduction <xref ref-type="bibr" rid="pone.0084230-Kang1">[7]</xref>. The rate of grade 3 or 4 hand–foot syndrome in capecitabine -based group was 3% in our pooled analysis, which was lower than reported in a previous study(11–17% in Westerners)<xref ref-type="bibr" rid="pone.0084230-Cassidy2">[32]</xref> suggesting ethnic differences existed. In contrast, toxic effects of S-1 have been reported to be more severe in patients from the USA than in Asian patients <xref ref-type="bibr" rid="pone.0084230-Hoff1">[33]</xref>, <xref ref-type="bibr" rid="pone.0084230-Ajani2">[34]</xref>, <xref ref-type="bibr" rid="pone.0084230-Chuah1">[35]</xref>. Besides, more S-1-treatment -related deaths have also been mentioned to occur in patients from the USA than Asia <xref ref-type="bibr" rid="pone.0084230-Boku2">[36]</xref>, resulting in different recommended doses in these populations. These findings warrant careful evaluation of patients appropriate for the regimen.</p>
<p>These two types of fluoropyrimidine have some different characteristics in the mechanism of their antitumor effect. Results from subset analysis of the FLAGS trial and JCOG9912 showed that S-1 was better than 5-FU in patients with gastric cancer associated with high dihydropyrimidine dehydrogenase (DPD), which was found more commonly in diffuse-type tumors than in intestinal-type tumors<xref ref-type="bibr" rid="pone.0084230-Yamada1">[37]</xref>. Expression of TP is reported to be lacking of association with the efficacy of S-1 or 5-FU in gastric cancer <xref ref-type="bibr" rid="pone.0084230-Napieralski1">[38]</xref> and colorectal cancer <xref ref-type="bibr" rid="pone.0084230-Salonga1">[39]</xref>, <xref ref-type="bibr" rid="pone.0084230-Ichikawa1">[40]</xref>. High TP expression in CRC is reported to be associated with higher efficacy of capecitabine-based therapy <xref ref-type="bibr" rid="pone.0084230-Meropol1">[41]</xref>. Therefore, the biomarkers DPD and TP may be candidates to select whether S-1 or capecitabine be suitable for each patient.</p>
<p>It is important to note the limitations of the present study. First, as with any meta-analysis, the results were affected by the quality of the individual studies. Four of the studies in our meta-analysis were RCTs and two were retrospective studies, while one abstract from ASCO conferences. Insufficient amount of data from abstract might potentially limit detection of the difference, and populations from retrospective studies might contain uncontrolled and potentially heterogeneous. Second, this meta-analysis was not based on individual patient data, which might overestimate treatments effects and preclude a more comprehensive analysis such as adjusting for baseline factors (ECOG status) and other differences that existed between the trials from which the data were pooled. Third, these studies were conducted at major academic institutions among patients with adequate major organ function and might not reflect the general patient population in the community or patients with organ dysfunction. Finally, all of the studies included in this analysis were from Asia, the results need confirmation in the West for the differences of efficacy and safety differed by ethnicities.</p>
<p>In conclusion, this is the first meta-analysis focused on the comparison of the efficacy and safety of S-1-based and capecitabine-based regimens. Stratified analyses were conducted, and the results were consistent with the previous studies. Additionally, no publication biases were detected, which indicated that the results may be unbiased. Our meta-analysis suggests that both the S-1-based and capecitabine-based regimens are equally active and well tolerated, and have the potential of backbone chemotherapy regimen in further studies of gastrointestinal cancers. More high-quality RCTs and Western studies are needed to confirm these findings. Further investigations are also needed to clarify the potential predictive factors for drug selection and to establish the effectiveness of various combinations, including molecular targeted agents.</p>
</sec><sec id="s5">
<title>Supporting Information</title>
<supplementary-material id="pone.0084230.s001" mimetype="application/msword" xlink:href="info:doi/10.1371/journal.pone.0084230.s001" position="float" xlink:type="simple"><label>Checklist S1</label><caption>
<p>A PRISMA checklist for this meta-analysis.</p>
<p>(DOC)</p>
</caption></supplementary-material></sec></body>
<back><ref-list>
<title>References</title>
<ref id="pone.0084230-Desauw1"><label>1</label>
<mixed-citation publication-type="other" xlink:type="simple">Desauw C (2010) [Epidemiology and risk factors of colorectal cancer]. Soins: 30–32.</mixed-citation>
</ref>
<ref id="pone.0084230-Shin1"><label>2</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shin</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>S</given-names></name> (<year>2011</year>) <article-title>Gastric cancer epidemiology in Korea</article-title>. <source>J Gastric Cancer</source> <volume>11</volume>: <fpage>135</fpage>–<lpage>140</lpage>.</mixed-citation>
</ref>
<ref id="pone.0084230-Shridhar1"><label>3</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shridhar</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Dombi</surname><given-names>GW</given-names></name>, <name name-style="western"><surname>Finkelstein</surname><given-names>SE</given-names></name>, <name name-style="western"><surname>Meredith</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Hoffe</surname><given-names>SE</given-names></name> (<year>2011</year>) <article-title>Improved survival in patients with lymph node-positive gastric cancer who received preoperative radiation: an analysis of the Surveillance, Epidemiology, and End Results database</article-title>. <source>Cancer</source> <volume>117</volume>: <fpage>3908</fpage>–<lpage>3916</lpage>.</mixed-citation>
</ref>
<ref id="pone.0084230-VanCutsem1"><label>4</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Van Cutsem</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Moiseyenko</surname><given-names>VM</given-names></name>, <name name-style="western"><surname>Tjulandin</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Majlis</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Constenla</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group</article-title>. <source>J Clin Oncol</source> <volume>24</volume>: <fpage>4991</fpage>–<lpage>4997</lpage>.</mixed-citation>
</ref>
<ref id="pone.0084230-Cunningham1"><label>5</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cunningham</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Okines</surname><given-names>AF</given-names></name>, <name name-style="western"><surname>Ashley</surname><given-names>S</given-names></name> (<year>2010</year>) <article-title>Capecitabine and oxaliplatin for advanced esophagogastric cancer</article-title>. <source>N Engl J Med</source> <volume>362</volume>: <fpage>858</fpage>–<lpage>859</lpage>.</mixed-citation>
</ref>
<ref id="pone.0084230-Koizumi1"><label>6</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Koizumi</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Narahara</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Hara</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Takagane</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Akiya</surname><given-names>T</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial</article-title>. <source>Lancet Oncol</source> <volume>9</volume>: <fpage>215</fpage>–<lpage>221</lpage>.</mixed-citation>
</ref>
<ref id="pone.0084230-Kang1"><label>7</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kang</surname><given-names>YK</given-names></name>, <name name-style="western"><surname>Kang</surname><given-names>WK</given-names></name>, <name name-style="western"><surname>Shin</surname><given-names>DB</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Xiong</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial</article-title>. <source>Ann Oncol</source> <volume>20</volume>: <fpage>666</fpage>–<lpage>673</lpage>.</mixed-citation>
</ref>
<ref id="pone.0084230-Cassidy1"><label>8</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cassidy</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Tabernero</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Twelves</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Brunet</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Butts</surname><given-names>C</given-names></name>, <etal>et al</etal>. (<year>2004</year>) <article-title>XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer</article-title>. <source>J Clin Oncol</source> <volume>22</volume>: <fpage>2084</fpage>–<lpage>2091</lpage>.</mixed-citation>
</ref>
<ref id="pone.0084230-deGramont1"><label>9</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>de Gramont</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Figer</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Seymour</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Homerin</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hmissi</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2000</year>) <article-title>Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer</article-title>. <source>J Clin Oncol</source> <volume>18</volume>: <fpage>2938</fpage>–<lpage>2947</lpage>.</mixed-citation>
</ref>
<ref id="pone.0084230-Schoffski1"><label>10</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schoffski</surname><given-names>P</given-names></name> (<year>2004</year>) <article-title>The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors</article-title>. <source>Anticancer Drugs</source> <volume>15</volume>: <fpage>85</fpage>–<lpage>106</lpage>.</mixed-citation>
</ref>
<ref id="pone.0084230-1"><label>11</label>
<mixed-citation publication-type="journal" xlink:type="simple"><article-title>Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer</article-title>. <source>J Clin Oncol</source> <volume>16</volume>: <fpage>301</fpage>–<lpage>308</lpage>.</mixed-citation>
</ref>
<ref id="pone.0084230-Maehara1"><label>12</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Maehara</surname><given-names>Y</given-names></name> (<year>2003</year>) <article-title>S-1 in gastric cancer: a comprehensive review</article-title>. <source>Gastric Cancer</source> <volume>6</volume> Suppl 1<fpage>2</fpage>–<lpage>8</lpage>.</mixed-citation>
</ref>
<ref id="pone.0084230-Ajani1"><label>13</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ajani</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Rodriguez</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Bodoky</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Moiseyenko</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Lichinitser</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial</article-title>. <source>J Clin Oncol</source> <volume>28</volume>: <fpage>1547</fpage>–<lpage>1553</lpage>.</mixed-citation>
</ref>
<ref id="pone.0084230-Okines1"><label>14</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Okines</surname><given-names>AF</given-names></name>, <name name-style="western"><surname>Norman</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>McCloud</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Kang</surname><given-names>YK</given-names></name>, <name name-style="western"><surname>Cunningham</surname><given-names>D</given-names></name> (<year>2009</year>) <article-title>Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer</article-title>. <source>Ann Oncol</source> <volume>20</volume>: <fpage>1529</fpage>–<lpage>1534</lpage>.</mixed-citation>
</ref>
<ref id="pone.0084230-Lee1"><label>15</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lee</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Kang</surname><given-names>YK</given-names></name>, <name name-style="western"><surname>Kang</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>KH</given-names></name>, <name name-style="western"><surname>Zang</surname><given-names>DY</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer</article-title>. <source>Br J Cancer</source> <volume>99</volume>: <fpage>584</fpage>–<lpage>590</lpage>.</mixed-citation>
</ref>
<ref id="pone.0084230-Kim1"><label>16</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kim</surname><given-names>GM</given-names></name>, <name name-style="western"><surname>Jeung</surname><given-names>HC</given-names></name>, <name name-style="western"><surname>Rha</surname><given-names>SY</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>HS</given-names></name>, <name name-style="western"><surname>Jung</surname><given-names>I</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer</article-title>. <source>Eur J Cancer</source> <volume>48</volume>: <fpage>518</fpage>–<lpage>526</lpage>.</mixed-citation>
</ref>
<ref id="pone.0084230-Seol1"><label>17</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Seol</surname><given-names>YM</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Choi</surname><given-names>YJ</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>GH</given-names></name>, <name name-style="western"><surname>Shin</surname><given-names>HJ</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study</article-title>. <source>Jpn J Clin Oncol</source> <volume>39</volume>: <fpage>43</fpage>–<lpage>48</lpage>.</mixed-citation>
</ref>
<ref id="pone.0084230-Shitara1"><label>18</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shitara</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Sawaki</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Matsuo</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kondo</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Takahari</surname><given-names>D</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>A retrospective comparison of S-1 plus cisplatin and capecitabine plus cisplatin for patients with advanced or recurrent gastric cancer</article-title>. <source>Int J Clin Oncol</source> <volume>18</volume>: <fpage>539</fpage>–<lpage>546</lpage>.</mixed-citation>
</ref>
<ref id="pone.0084230-Hong1"><label>19</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hong</surname><given-names>YS</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>YS</given-names></name>, <name name-style="western"><surname>Lim</surname><given-names>HY</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>TW</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial</article-title>. <source>Lancet Oncol</source> <volume>13</volume>: <fpage>1125</fpage>–<lpage>1132</lpage>.</mixed-citation>
</ref>
<ref id="pone.0084230-Parmar1"><label>20</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Parmar</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Torri</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Stewart</surname><given-names>L</given-names></name> (<year>1998</year>) <article-title>Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints</article-title>. <source>Stat Med</source> <volume>17</volume>: <fpage>2815</fpage>–<lpage>2834</lpage>.</mixed-citation>
</ref>
<ref id="pone.0084230-Therasse1"><label>21</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Therasse</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Arbuck</surname><given-names>SG</given-names></name>, <name name-style="western"><surname>Eisenhauer</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>Wanders</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Kaplan</surname><given-names>RS</given-names></name>, <etal>et al</etal>. (<year>2000</year>) <article-title>New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada</article-title>. <source>J Natl Cancer Inst</source> <volume>92</volume>: <fpage>205</fpage>–<lpage>216</lpage>.</mixed-citation>
</ref>
<ref id="pone.0084230-Sutton1"><label>22</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sutton</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Gilbody</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Abrams</surname><given-names>KR</given-names></name> (<year>2000</year>) <article-title>Modelling publication bias in meta-analysis: a review</article-title>. <source>Stat Methods Med Res</source> <volume>9</volume>: <fpage>421</fpage>–<lpage>445</lpage>.</mixed-citation>
</ref>
<ref id="pone.0084230-Begg1"><label>23</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Begg</surname><given-names>CB</given-names></name>, <name name-style="western"><surname>Mazumdar</surname><given-names>M</given-names></name> (<year>1994</year>) <article-title>Operating characteristics of a rank correlation test for publication bias</article-title>. <source>Biometrics</source> <volume>50</volume>: <fpage>1088</fpage>–<lpage>1101</lpage>.</mixed-citation>
</ref>
<ref id="pone.0084230-Egger1"><label>24</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Egger</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Davey Smith</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Schneider</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Minder</surname><given-names>C</given-names></name> (<year>1997</year>) <article-title>Bias in meta-analysis detected by a simple, graphical test</article-title>. <source>BMJ</source> <volume>315</volume>: <fpage>629</fpage>–<lpage>634</lpage>.</mixed-citation>
</ref>
<ref id="pone.0084230-Zang1"><label>25</label>
<mixed-citation publication-type="other" xlink:type="simple">Zang DY, Chung I-J, Oh HS, Park KU, Lee KH (2012) Randomized phase II study of oxaliplatin and S-1 (OS) versus oxaliplatin and capecitabine (XELOX) in patients with advanced or recurrent colorectal cancer. J Clin Oncol 2012;595 (Abstract).</mixed-citation>
</ref>
<ref id="pone.0084230-Boku1"><label>26</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Boku</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Yamamoto</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Shirao</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Doi</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Sawaki</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912)</article-title>. <source>J Clin Oncol</source> <volume>25</volume>: <fpage>965 s</fpage> (Abstract)..</mixed-citation>
</ref>
<ref id="pone.0084230-Cunningham2"><label>27</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cunningham</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Starling</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Rao</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Iveson</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Nicolson</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>Capecitabine and oxaliplatin for advanced esophagogastric cancer</article-title>. <source>N Engl J Med</source> <volume>358</volume>: <fpage>36</fpage>–<lpage>46</lpage>.</mixed-citation>
</ref>
<ref id="pone.0084230-Bang1"><label>28</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bang</surname><given-names>YJ</given-names></name>, <name name-style="western"><surname>Van Cutsem</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Feyereislova</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Chung</surname><given-names>HC</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>L</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial</article-title>. <source>Lancet</source> <volume>376</volume>: <fpage>687</fpage>–<lpage>697</lpage>.</mixed-citation>
</ref>
<ref id="pone.0084230-Ohtsu1"><label>29</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ohtsu</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Shah</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Van Cutsem</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Rha</surname><given-names>SY</given-names></name>, <name name-style="western"><surname>Sawaki</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study</article-title>. <source>J Clin Oncol</source> <volume>29</volume>: <fpage>3968</fpage>–<lpage>3976</lpage>.</mixed-citation>
</ref>
<ref id="pone.0084230-Sakamoto1"><label>30</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sakamoto</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Chin</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kondo</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kojima</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Terashima</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer</article-title>. <source>Anticancer Drugs</source> <volume>17</volume>: <fpage>231</fpage>–<lpage>236</lpage>.</mixed-citation>
</ref>
<ref id="pone.0084230-Sakata1"><label>31</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sakata</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Ohtsu</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Horikoshi</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Sugimachi</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Mitachi</surname><given-names>Y</given-names></name>, <etal>et al</etal>. (<year>1998</year>) <article-title>Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients</article-title>. <source>Eur J Cancer</source> <volume>34</volume>: <fpage>1715</fpage>–<lpage>1720</lpage>.</mixed-citation>
</ref>
<ref id="pone.0084230-Cassidy2"><label>32</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cassidy</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Twelves</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Van Cutsem</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Hoff</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Bajetta</surname><given-names>E</given-names></name>, <etal>et al</etal>. (<year>2002</year>) <article-title>First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin</article-title>. <source>Ann Oncol</source> <volume>13</volume>: <fpage>566</fpage>–<lpage>575</lpage>.</mixed-citation>
</ref>
<ref id="pone.0084230-Hoff1"><label>33</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hoff</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Saad</surname><given-names>ED</given-names></name>, <name name-style="western"><surname>Ajani</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Lassere</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Wenske</surname><given-names>C</given-names></name>, <etal>et al</etal>. (<year>2003</year>) <article-title>Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors</article-title>. <source>Clin Cancer Res</source> <volume>9</volume>: <fpage>134</fpage>–<lpage>142</lpage>.</mixed-citation>
</ref>
<ref id="pone.0084230-Ajani2"><label>34</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ajani</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Faust</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ikeda</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Yao</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Anbe</surname><given-names>H</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma</article-title>. <source>J Clin Oncol</source> <volume>23</volume>: <fpage>6957</fpage>–<lpage>6965</lpage>.</mixed-citation>
</ref>
<ref id="pone.0084230-Chuah1"><label>35</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chuah</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Goh</surname><given-names>BC</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Soong</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Lau</surname><given-names>F</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients</article-title>. <source>Cancer Sci</source> <volume>102</volume>: <fpage>478</fpage>–<lpage>483</lpage>.</mixed-citation>
</ref>
<ref id="pone.0084230-Boku2"><label>36</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Boku</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Yamamoto</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Fukuda</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Shirao</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Doi</surname><given-names>T</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study</article-title>. <source>Lancet Oncol</source> <volume>10</volume>: <fpage>1063</fpage>–<lpage>1069</lpage>.</mixed-citation>
</ref>
<ref id="pone.0084230-Yamada1"><label>37</label>
<mixed-citation publication-type="other" xlink:type="simple">Yamada Y, Yamamoto S (2009) Impact of dihydropyrimidine dehydrogenase status of biopsy specimens on efficacy of irinotecan plus cisplatin, S-1, or 5-FU as first-line treatment of advanced gastric cancer patients in JCOG9912. J Clin Oncol<volume>27</volume>: :15 s (Abstr 4535).</mixed-citation>
</ref>
<ref id="pone.0084230-Napieralski1"><label>38</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Napieralski</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Ott</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kremer</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Specht</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Vogelsang</surname><given-names>H</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients</article-title>. <source>Clin Cancer Res</source> <volume>11</volume>: <fpage>3025</fpage>–<lpage>3031</lpage>.</mixed-citation>
</ref>
<ref id="pone.0084230-Salonga1"><label>39</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Salonga</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Danenberg</surname><given-names>KD</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Metzger</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Groshen</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>2000</year>) <article-title>Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase</article-title>. <source>Clin Cancer Res</source> <volume>6</volume>: <fpage>1322</fpage>–<lpage>1327</lpage>.</mixed-citation>
</ref>
<ref id="pone.0084230-Ichikawa1"><label>40</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ichikawa</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Uetake</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Shirota</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Yamada</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Nishi</surname><given-names>N</given-names></name>, <etal>et al</etal>. (<year>2003</year>) <article-title>Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer</article-title>. <source>Clin Cancer Res</source> <volume>9</volume>: <fpage>786</fpage>–<lpage>791</lpage>.</mixed-citation>
</ref>
<ref id="pone.0084230-Meropol1"><label>41</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Meropol</surname><given-names>NJ</given-names></name>, <name name-style="western"><surname>Gold</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Diasio</surname><given-names>RB</given-names></name>, <name name-style="western"><surname>Andria</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Dhami</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer</article-title>. <source>J Clin Oncol</source> <volume>24</volume>: <fpage>4069</fpage>–<lpage>4077</lpage>.</mixed-citation>
</ref>
</ref-list></back>
</article>